Review
doi: 10.1002/cpt.1017.
Epub 2018 Mar 8.
Challenges and Opportunities With Oncology Drug Development in China
Affiliations
- PMID: 29328503
- DOI: 10.1002/cpt.1017
Item in Clipboard
Review
Challenges and Opportunities With Oncology Drug Development in China
Clin Pharmacol Ther.
2019 Feb.
Abstract
Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.
© 2018 American Society for Clinical Pharmacology and Therapeutics.
Similar articles
-
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.Clin Pharmacol Ther. 2019 Jun;105(6):1303-1320. doi: 10.1002/cpt.1352. Epub 2019 Feb 25. Clin Pharmacol Ther. 2019. PMID: 30802932 Review. No abstract available.
-
Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.Lancet Oncol. 2019 Nov;20(11):e619-e626. doi: 10.1016/S1470-2045(19)30491-7. Lancet Oncol. 2019. PMID: 31674320
-
New drug approvals in oncology.Nat Rev Clin Oncol. 2020 Mar;17(3):140-146. doi: 10.1038/s41571-019-0313-2. Epub 2020 Feb 4. Nat Rev Clin Oncol. 2020. PMID: 32020042 Review.
-
Cancer drug development in China: recent advances and future challenges.Drug Discov Today. 2015 Jun;20(6):766-71. doi: 10.1016/j.drudis.2014.11.005. Epub 2014 Nov 20. Drug Discov Today. 2015. PMID: 25463037 Review.
-
Challenges and opportunities in oncology drug development and clinical research in China.Cell. 2024 Mar 28;187(7):1578-1583. doi: 10.1016/j.cell.2024.02.040. Cell. 2024. PMID: 38552607
Cited by
-
The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.Lancet Reg Health West Pac. 2022 Dec 28;32:100670. doi: 10.1016/j.lanwpc.2022.100670. eCollection 2023 Mar. Lancet Reg Health West Pac. 2022. PMID: 36785854 Free PMC article.
-
Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China.Ther Innov Regul Sci. 2023 Nov;57(6):1314-1321. doi: 10.1007/s43441-023-00572-8. Epub 2023 Aug 31. Ther Innov Regul Sci. 2023. PMID: 37651044
-
Factors influencing willingness to participate in ophthalmic clinical trials and strategies for effective recruitment.Int J Ophthalmol. 2024 Jan 18;17(1):157-163. doi: 10.18240/ijo.2024.01.21. eCollection 2024. Int J Ophthalmol. 2024. PMID: 38239943 Free PMC article.
-
Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.Int J Environ Res Public Health. 2022 Mar 1;19(5):2857. doi: 10.3390/ijerph19052857. Int J Environ Res Public Health. 2022. PMID: 35270550 Free PMC article.
-
Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.J Clin Pharmacol. 2021 Aug;61(8):1045-1053. doi: 10.1002/jcph.1821. Epub 2021 Feb 14. J Clin Pharmacol. 2021. PMID: 33501654 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
